<p>MeiraGTx Holdings plc has entered into an exclusive license agreement with ZipBio, a biotechnology company specializing in AI-driven protein therapeutics. Under the terms of the agreement, MeiraGTx will gain exclusive rights to develop and commercialize ZipBio’s first-in-class therapies for Geographic Atrophy, which target the complement pathway. The collaboration combines MeiraGTx’s expertise in genetic medicine development and manufacturing with ZipBio’s proprietary AI-based protein design platform, COMPACT™. The agreement includes upfront, milestone, and royalty payments, though specific financial terms were not disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY76566) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Reuters

VG Health

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares US Pharma

Ark Genomic Revolution ETF

TG Therap

MeiraGTx

SPDR S&P Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

MeiraGTx Signs Exclusive License Agreement With ZipBio for Geographic Atrophy Gene Therapy